14-3-3η Autoantibodies : Diagnostic Use in Early Rheumatoid Arthritis
OBJECTIVE: To describe the expression and diagnostic use of 14-3-3η autoantibodies in early rheumatoid arthritis (RA).
METHODS: 14-3-3η autoantibody levels were measured using an electrochemiluminescent multiplexed assay in 500 subjects (114 disease-modifying antirheumatic drug-naive patients with early RA, 135 with established RA, 55 healthy, 70 autoimmune, and 126 other non-RA arthropathy controls). 14-3-3η protein levels were determined in an earlier analysis. Two-tailed Student t tests and Mann-Whitney U tests compared differences among groups. Receiver-operator characteristic (ROC) curves were generated and diagnostic performance was estimated by area under the curve (AUC), as well as specificity, sensitivity, and likelihood ratios (LR) for optimal cutoffs.
RESULTS: Median serum 14-3-3η autoantibody concentrations were significantly higher (p < 0.0001) in patients with early RA (525 U/ml) when compared with healthy controls (235 U/ml), disease controls (274 U/ml), autoimmune disease controls (274 U/ml), patients with osteoarthritis (259 U/ml), and all controls (265 U/ml). ROC curve analysis comparing early RA with healthy controls demonstrated a significant (p < 0.0001) AUC of 0.90 (95% CI 0.85-0.95). At an optimal cutoff of ≥ 380 U/ml, the ROC curve yielded a sensitivity of 73%, a specificity of 91%, and a positive LR of 8.0. Adding 14-3-3η autoantibodies to 14-3-3η protein positivity enhanced the identification of patients with early RA from 59% to 90%; addition of 14-3-3η autoantibodies to anticitrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) increased identification from 72% to 92%. Seventy-two percent of RF- and ACPA-seronegative patients were positive for 14-3-3η autoantibodies.
CONCLUSION: 14-3-3η autoantibodies, alone and in combination with the 14-3-3η protein, RF, and/or ACPA identified most patients with early RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 42(2015), 9 vom: 23. Sept., Seite 1587-94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maksymowych, Walter P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
14-3-3 PROTEINS |
|---|
| Anmerkungen: |
Date Completed 06.06.2016 Date Revised 02.09.2015 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.141385 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250917645 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250917645 | ||
| 003 | DE-627 | ||
| 005 | 20231224160847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.141385 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0836.xml |
| 035 | |a (DE-627)NLM250917645 | ||
| 035 | |a (NLM)26178283 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maksymowych, Walter P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 14-3-3η Autoantibodies |b Diagnostic Use in Early Rheumatoid Arthritis |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2016 | ||
| 500 | |a Date Revised 02.09.2015 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To describe the expression and diagnostic use of 14-3-3η autoantibodies in early rheumatoid arthritis (RA) | ||
| 520 | |a METHODS: 14-3-3η autoantibody levels were measured using an electrochemiluminescent multiplexed assay in 500 subjects (114 disease-modifying antirheumatic drug-naive patients with early RA, 135 with established RA, 55 healthy, 70 autoimmune, and 126 other non-RA arthropathy controls). 14-3-3η protein levels were determined in an earlier analysis. Two-tailed Student t tests and Mann-Whitney U tests compared differences among groups. Receiver-operator characteristic (ROC) curves were generated and diagnostic performance was estimated by area under the curve (AUC), as well as specificity, sensitivity, and likelihood ratios (LR) for optimal cutoffs | ||
| 520 | |a RESULTS: Median serum 14-3-3η autoantibody concentrations were significantly higher (p < 0.0001) in patients with early RA (525 U/ml) when compared with healthy controls (235 U/ml), disease controls (274 U/ml), autoimmune disease controls (274 U/ml), patients with osteoarthritis (259 U/ml), and all controls (265 U/ml). ROC curve analysis comparing early RA with healthy controls demonstrated a significant (p < 0.0001) AUC of 0.90 (95% CI 0.85-0.95). At an optimal cutoff of ≥ 380 U/ml, the ROC curve yielded a sensitivity of 73%, a specificity of 91%, and a positive LR of 8.0. Adding 14-3-3η autoantibodies to 14-3-3η protein positivity enhanced the identification of patients with early RA from 59% to 90%; addition of 14-3-3η autoantibodies to anticitrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) increased identification from 72% to 92%. Seventy-two percent of RF- and ACPA-seronegative patients were positive for 14-3-3η autoantibodies | ||
| 520 | |a CONCLUSION: 14-3-3η autoantibodies, alone and in combination with the 14-3-3η protein, RF, and/or ACPA identified most patients with early RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 14-3-3 PROTEINS | |
| 650 | 4 | |a AUTOANTIBODIES | |
| 650 | 4 | |a DIAGNOSIS | |
| 650 | 4 | |a RHEUMATOID ARTHRITIS | |
| 650 | 7 | |a 14-3-3 Proteins |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Boire, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a van Schaardenburg, Dirkjan |e verfasserin |4 aut | |
| 700 | 1 | |a Wichuk, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Turk, Samina |e verfasserin |4 aut | |
| 700 | 1 | |a Boers, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Siminovitch, Katherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Bykerk, Vivian |e verfasserin |4 aut | |
| 700 | 1 | |a Keystone, Ed |e verfasserin |4 aut | |
| 700 | 1 | |a Tak, Paul Peter |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuijk, Arno W |e verfasserin |4 aut | |
| 700 | 1 | |a Landewé, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a van der Heijde, Desiree |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Mairead |e verfasserin |4 aut | |
| 700 | 1 | |a Marotta, Anthony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 42(2015), 9 vom: 23. Sept., Seite 1587-94 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2015 |g number:9 |g day:23 |g month:09 |g pages:1587-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.141385 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2015 |e 9 |b 23 |c 09 |h 1587-94 | ||